Roche buys biotech Promedior in $1.39 billion deal

The Swiss drugmaker will pay $390 million upfront for the privately held biotechnology company specializing in the development of targeted medicines to treat fibrosis.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news